Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrent After Hepatectomy in High Risk Patients -A Phase II Study

NCT02447679 is registered in ClinicalTrials.gov with Chang Gung Memorial Hospital as lead sponsor.

NCT NCT02447679
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02447679 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrent After Hepatectomy in High Risk Patients -A Phase II Study
Lead sponsor
Chang Gung Memorial Hospital
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2010
Completion date
February 2, 2017
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adult hepatocellular carcinoma, adverse reaction to drug, recurrent hepatocellular carcinoma, vascular endothelial growth factor overexpression